Jim Cramer is pounding the table with a bullish call on drug companies.
"Can pharma go from roving bear market to a raging bull status like so many other sectors have done in recent months?" the "Mad Money" host asks.
Cramer sees bright spots that the worst may be over.
"Here's the bottom line. We have an awful lot of signs the drought is over," Cramer said. "So my conclusion is yes, I say it is time to buy."
The "Halftime Report" experts discuss the sector.
Stephen Weiss sees opportunity elsewhere. "I like the big cap biotech sector better," he argued. Weiss is concerned Presidential campaign politics may drag down drug company performance.
John Spallanzani thinks the sector is in a holding period. "We have to see how it is going to trade because investors sold on news today," he said.
Jon Najarian is a believer in AbbVie and Abbot Labs. He likes the stocks on recent M&A moves and strong performance.
Trader disclosure: On April 29, 2016, the following stocks and commodities mentioned or intended to be mentioned on CNBC's "Fast Money" were owned by the "Halftime Report" traders:
JOSH BROWN: Long AAPL, BABA, CORE, DE, DNKN, GE, LNKD, SAM, SHAK, TWTR, XLE
JON NAJARIAN: Long BMY, CHS, DIS, NFLX, PEP, PFE, RAX, SPRT Long Calls AMZN, AREX, BAX, COP, CRM, DHR, ECA, FIT, GDX, GRPN, LVS, MDLZ, MSFT, NBR, P, PDS, QCOM, SLW, XOM, YHOO, YNDX, ZIOP
STEVE WEISS: Long AAL, AMLP, CVC, ENBL, EPD, JD, PAA, SRPT, TLLP Short Puts: SRPT
—By CNBC Producer Bree Kelly. Follow her on Twitter @Bree_Kelly